References

1000000



Mifepristone-Misoprostol Medical Abortion Mortality



Search	
No Results	

Sea	arch	
No	Results	

Medscape

Saturday, April 25, 2020 News & Perspective Drugs & Diseases CME & Education Academy Video

Medscape General Medicine > MedGenMed Ob/Gyn & Women's Health > Contemporary Issues in Ob/Gyn & Women's Health

Mifepristone-Misoprostol Medical Abortion Mortality

Mitchell Creinin, MD; Paul Blumenthal, MD, MPH; Lee Shulman, MD DISCLOSURES | Medscape General Medicine. 2006;8(2):26

Medical abortion is a non-surgical option for women who elect to terminate a pregnancy. In September 2000, the United States Food and Drug Administration (FDA) approved a medical abortion regimen for women up to 49 days gestation consisting of 600 mg mifepristone (a progesterone antagonist) followed 36 to 48 hours later by 400 mg oral misoprostol (a prostaglandin analogue). Women return to the office 2 days after taking the mifepristone to be evaluated and to receive the misoprostol tablets; follow-up

Mifepristone-Misoprostol Medical Abortion Mortality

occurs in approximately 2 weeks. However, a number of alternative evidence-based regimens have become common in clinical practice in the United States and around the world. Such "off-label" use of medications frequently becomes the local "standard of care" when there is sufficient evidence that the off-label use is effective and has benefit for the patient. With regard to medical abortion, rigorous research and evaluation in clinical trials of these alternative regimens indicate they offer clinical benefit to patients.^[1] In the United States, the most common deviations from the FDA-approved regimen are the following:

To continue reading this article ...

Log In

or

Register for Free

What to Read Next on Medscape

Special Coverage: COVID-19

Recommended Reading

2001/viewarticle/897735 NEWS Mifepristone-Misoprostol More Effective Than Misoprostol in Pregnancy Loss



2002252560-overview DISEASES & CONDITIONS Elective Abortion

2010mifeprex-korlym-mifepristone-343130 DRUGS mifepristone

2002266317-overview DISEASES & CONDITIONS Early Pregnancy Loss



Most Popular Articles According to OBSTETRICIAN / GYNECOLOGISTS 1. Mother-Baby Separation for COVID-19 Not Evidence-Based, Experts Say
 Guidance on COVID-19 During Pregnancy and the Puerperium (ISUOG, 2020)
3. Alcohol, AFib, and Women: A Hazardous Mix?
4. UK Guidance on COVID-19 Infection in Pregnancy
5. Don't Separate Moms With COVID-19 From Newborns, Experts Say
View More



b:recommendationscuratedHasData : false

Medscape

FIND US ON



ABOUT

About Medscape	
Privacy Policy	
Editorial Policy	
Cookies	
Terms of Use	
Advertising Policy	
Help Center	
MEMBERSHIP	
Become a Member	
Email Newsletters	
Manage My Account	
APPS	
Medscape	
CME & Education	

WEBMD NETWORK

WebMD MedicineNet

eMedicineHealth

RxList

WebMD Corporate

EDITIONS

English

Deutsch

Español

Français

Português

All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

Close